



UNITED STATES PATENT AND TRADEMARK OFFICE

CH
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,974	08/18/2003	Martin Michaelis	DEAV20020064US NP	3394

5487 7590 07/03/2007

ROSS J. OEHLER
SANOFI-AVENTIS U.S. LLC
1041 ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

EXAMINER

KWON, BRIAN YONG S

ART UNIT	PAPER NUMBER
----------	--------------

1614

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

07/03/2007

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com
andrea.ryan@sanofi-aventis.com

Art Unit: 1614

Non-Responsive Election of Species Requirement

Applicants election, with traverse, with the Group II along with (N-[(S)-2-dipheylamino-2-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide is acknowledged.

As seen in the restriction/election requirement mailed 12/07/06 (page 3) below, the examiner also required the election of a single disclosed species from diseases.

3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from the compound(s) and disease(s), for example (i) (N-[(S)-2-dipheylamino-2-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide) and (ii) arthritis pain, under the instant claims of the elected Group. Moreover, whatever specific compound and disease are ultimately elected, applicants are required to list all claims readable thereon.

However, the applicant's response does not contain a single disclosed species from "pain" diseases or condition and is considered non-responsive. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Since the above-mentioned amendment appears to be a *bona fide* attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

BRIAN-YONG S. KWON
PRIMARY EXAMINER

